Compare EIG & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | PHAR |
|---|---|---|
| Founded | 2000 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.6M | 925.2M |
| IPO Year | 2006 | 2020 |
| Metric | EIG | PHAR |
|---|---|---|
| Price | $45.54 | $12.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 164.6K | 14.5K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $858,700,000.00 | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | $1.26 | $2.51 |
| P/E Ratio | ★ $85.52 | $3,041.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.73 | $9.54 |
| 52 Week High | $47.91 | $21.34 |
| Indicator | EIG | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 75.02 | 44.13 |
| Support Level | $41.01 | $12.98 |
| Resistance Level | $46.25 | $13.61 |
| Average True Range (ATR) | 0.91 | 0.39 |
| MACD | 0.17 | 0.09 |
| Stochastic Oscillator | 100.00 | 63.99 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations through its wholly owned subsidiaries.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.